Effect of Physical Activity on the Course of Parkinson's Disease in Patients With Bilateral DBS-STN Stimulation - a Randomized Controlled Trial.
EPA-DBS
1 other identifier
interventional
102
1 country
1
Brief Summary
Parkinson's disease is a common, progressive neurodegenerative disorder. The degeneration of dopaminergic neurons is associated with characteristic clinical symptoms such as tremor, rigidity, slowness of movement (bradykinesia) and postural instability. Subthalamic nucleus deep brain stimulation (DBS-STN) is a recognized and widely used method of treating advanced stages of Parkinson's disease. It improves clinical symptoms such as tremor, rigidity and slowness of movement (bradykinesia). This method has limited application for late motor and non-motor symptoms such as: akinesia, postural instability, gait, including the phenomenon of "freezing", recurrent falls, balance and dysarthria. These symptoms reduce the quality of life of patients and make them dependent on their caregivers. There is a clear need to develop additional forms of therapy that complement deep brain stimulation in controlling late motor and non-motor symptoms. Physical activity is a commonly used and recommended form of therapy for patients with Parkinson's disease and a complement to pharmacological therapy, improving gait, balance and quality of life. However, there are no clear recommendations including patients after implantation of DBS-STN stimulators to the group undergoing physiotherapy. To this day, only one clinical trial has been registered assessing the effect of physiotherapy on balance and gait in patients with DBS-STN.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable parkinson-disease
Started Sep 2024
Longer than P75 for not_applicable parkinson-disease
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 5, 2024
CompletedFirst Submitted
Initial submission to the registry
September 17, 2026
CompletedFirst Posted
Study publicly available on registry
September 24, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 5, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 5, 2028
September 24, 2026
June 1, 2026
3 years
September 17, 2026
September 17, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Part III UPDRS-MDS
Change in full ON-state score (Drugs+DBS) in Part III of the UPDRS-MDS Scale before and after study completion in control vs. study and subsequent study time points.
2 years
Secondary Outcomes (4)
Tinetti Scale
2 years
NFOG-Q
2 years
Berg Balance Scale
2 years
MoCA Scale
2 years
Study Arms (2)
Research group
EXPERIMENTALControl group
SHAM COMPARATORInterventions
Assessment of the patient's functional status: 10 Meter Walk (10 MW) Test, Tinetti Test, New Freezing of Gait Questionnaire (NFOG-Q), History of Falling Questionaire, Timed up and go (TUG), TUG - countdown from 100 to 80, TUG - cup half-filled with water carried in the right and left hand, TST - 10 s standing in a tandem position, 180 Tandem Pivot Test, TWT - Tandem Walking Test, Functional Reach test, Functional strength test, TEST Six Minute Walk (6MWT), Berg Balance Scale, Treadmill Gait Analysis, Platform Stabilometry Test.
Direct education of the patient in the field of self-care, counseling and instruction on independent exercise, use of medical equipment or devices, also at home.
Eligibility Criteria
You may qualify if:
- Patients diagnosed with idiopathic Parkinson's disease (ICD-10:G20).
- Patients qualified for advanced therapies using DBS-STN.
- Grade II-IV on the Hoehn \& Yahr scale.
- Age 50-70.
- Consent to participate in the study.
You may not qualify if:
- Patients diagnosed with atypical parkinsonism.
- Patients not eligible for advanced therapies with DBS-STN.
- Hoehn \& Yahr Grade I and V.
- Age \<50 and \>70
- Patients diagnosed with dementia syndrome (MMSE \< 24/30).
- Diseases of the osteoarticular system and muscles that make it impossible to undergo rehabilitation.
- Severe kidney, liver and heart failure.
- Active malignancy or malignancy diagnosed and treated within 3 years prior to the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Neurology, Faculty of Health Sciences, Bródnowski Mazovian Hospital
Warsaw, 03-242, Poland
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 17, 2026
First Posted
September 24, 2026
Study Start
September 5, 2024
Primary Completion (Estimated)
September 5, 2027
Study Completion (Estimated)
September 5, 2028
Last Updated
September 24, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will not share